Beryl Drugs
21.50
-1.12(-4.95%)
Market Cap₹10.93 Cr
PE Ratio754.00
IndustryHealthcare
Company Performance:
1D-4.95%
1M+5.24%
6M-6.52%
1Y-6.40%
5Y+295.95%
View Company Insightsright
More news about Beryl Drugs
20Mar 26
Beryl Drugs Limited Board Meeting Scheduled for April 1, 2026 to Consider EOGM Notice and Director Appointments
Beryl Drugs Limited has scheduled a board meeting for April 1, 2026, at 11:00 AM to consider an EOGM notice for director appointments and related party transactions. The agenda includes regularizing Mr. Shailendra Pathak as Whole Time Director, appointing Mrs. Neha Sarda as Independent Director, and approving material transactions with M/s. Aminova Infusions P. Ltd. Additional matters include appointing internal auditor Abhay Bhandari & Associates for FY 2026-2027 and various administrative functions.
 no imag found
17Mar 26
Beryl Drugs Promoter Sudhir Sethi Acquires Additional 5,000 Shares Worth ₹1.01 Lakh
Beryl Drugs Limited disclosed that promoter and director Sudhir Sethi acquired 5,000 shares worth ₹1.01 lakh through market transactions on 16-03-2026, increasing his shareholding from 9.33% to 9.42%. The transaction was disclosed under SEBI Insider Trading Regulations, demonstrating continued promoter confidence in the pharmaceutical company.
 no imag found
09Feb 26
Beryl Drugs Limited Reports Q3 FY26 Net Loss of ₹16.77 Lacs Amid Manufacturing Challenges
Beryl Drugs Limited reported a net loss of ₹16.77 lacs in Q3 FY26 versus a profit of ₹5.22 lacs in Q3 FY25, with revenue declining 28.87% to ₹377.68 lacs. The pharmaceutical company faced operational disruptions due to manufacturing facility suspension from February to November 2025 following FDA directions. Operations resumed on November 28, 2025, after regulatory compliance, positioning the company for potential recovery in subsequent quarters.
 no imag found
06Jan 26
Beryl Drugs Limited Files Q3FY26 Compliance Under Regulation 57(5) Stating Non-Applicability
Beryl Drugs Limited filed its Q3FY26 compliance under Regulation 57(5) with BSE on 6th January, 2026, stating the regulation is not applicable as the company has no non-convertible securities requiring interest, dividend, or principal payments for the quarter ended 31st December, 2025. The filing was authorized by Chairman & Director Sudhir Sethi.
 no imag found
05Jan 26
Beryl Drugs Appoints Directors Under SEBI Regulation 30 Compliance Framework
Beryl Drugs Limited announced board appointments under SEBI Regulation 30 compliance, appointing Mr. Shailendra Pathak (40 years experience, electrical engineering) as Whole Time Director and Mrs. Neha Sarda (CS, 14 years finance experience) as Independent Director, both subject to shareholder approval.
 no imag found
07Aug 25
Beryl Drugs Reports Q1 Net Profit of Rs 2.11 Lakhs Amid Partial Manufacturing Suspension
Beryl Drugs Limited announced a turnaround to profitability for Q1 ended June 30, with a net profit of Rs 2.11 lakhs compared to a net loss of Rs 36.79 lakhs in the previous year's Q1. Revenue from operations increased to Rs 483.58 lakhs from Rs 287.73 lakhs. The company's manufacturing facility is partially under suspension and upgradation, impacting the turnover for the entire quarter. Despite this, Beryl Drugs improved its financial performance significantly. Total expenses decreased to Rs 476.61 lakhs, and earnings per share stood at Rs 0.04.
 no imag found
Beryl Drugs
21.50
-1.12
(-4.95%)
1 Year Returns:-6.40%
Industry Peers
Sun Pharmaceutical
1,620.40
(-3.55%)
Divis Laboratories
6,361.50
(-0.27%)
Torrent Pharmaceuticals
4,117.20
(-0.72%)
Dr Reddys Laboratories
1,317.10
(-1.04%)
Lupin
2,296.10
(-1.93%)
Cipla
1,295.00
(-0.83%)
Mankind Pharma
2,267.40
(-1.11%)
Zydus Life Science
927.40
(-2.00%)
Aurobindo Pharma
1,413.80
(-1.50%)
Glenmark Pharmaceuticals
2,299.50
(-1.52%)